Clinical Trials Logo

Clinical Trial Summary

Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiatory airflow limitation. This definition was reached by consensus, based on consideration of the characteristics that are typical of asthma and that distinguish it from other respiratory conditions .

Asthma is a problem worldwide, with an estimated 300 million affected individuals .It appears that the global prevalence of asthma ranges from 1% to 18% of the population in different countries .


Clinical Trial Description

Over the past years, an increase in the number of emergency department (ED) visits for asthma exacerbation has been reported. Most of these visits are for preschool children.

Although pulmonary function tests are commonly used to assess the severity of acute asthma in adults, they are difficult to perform in children, especially those who are younger than five years old .

spirometry measures pulmonary markers such as vital capacity and maximal forced expiatory volume in 1 second. Well-trained personnel are required to perform these tests, and they are not routinely available in the ED. Peak flow has been used in the ED to measure the degree of respiratory obstruction .This technique is difficult to perform in children less than 6 years of age because of their lack of coordination and comprehension .

Adequate evaluation of the severity of asthma exacerbation is important for the initial management of patients, as well as for assessing the clinical response. However, severity is more difficult to assess in children. The clinical evaluation and physician's experience are often not enough to determine the degree of respiratory obstruction .

In the emergency room setting, the most critical issue facing the attending physician is, deciding the adequacy of outpatient therapy of acute asthma, or when hospitalization is indicated. Traditionally, this decision is used to be made according to the clinical history, physical examination, laboratory results and response to therapy of the patient .

A number of asthma severity measures or scoring systems have been established to estimate the degree of airway obstruction for children in whom the standard measurements cannot be performed. These systems combine a number of physical signs, such as respiratory rate and accessory muscle use, to form an aggregate score that estimates the severity of an acute asthma exacerbation .no scoring system is perfect, but some method of assessing severity in children is needed when spirometry testing is not obtainable.

modified the pulmonary index was reported by adding 2 scoring items, namely heart rate and SpO2 at room temperature, and by dividing the method of heart rate and respiratory rate scoring depending on which of 2 age groups the patient belong to. Modified Pulmonary Index Score is a quantitative method of evaluating respiratory conditions in asthmatic subjects modified and consists of 6 evaluation items, which are important for the assessment of dyspnea and are relatively easy to assess in clinical practice, namely heart rate, respiratory rate, accessory muscle use, inspiratory to expiatory flow ratio, degree of wheezing, and oxygen saturation in room air.

the predictive validity and reproducibility of the Modified Pulmonary Index Score for asthma exacerbation was reported in 30 children with a mean age of 7.6 ± 5.5 years in 2005. They found good correlations of the Modified Pulmonary Index Score with clinical outcomes such as ICU admission. The Modified Pulmonary Index Score appears to be suitable for measuring the severity of acute asthma exacerbation, and was applied as primary outcome measurement in some clinical trials .

A significant correlation between Modified Pulmonary Index Score at hospitalization and hospitalization period in children above 5 years old, suggesting that Modified Pulmonary Index Score was useful for predicting the clinical course after hospitalization. However, its applicability to preschool children has not yet been fully elucidated.

The Modified Pulmonary Index Score can be a useful tool for several aspects during acute asthma attacks, including the determination of a treatment plan, and prediction of the period of hospitalization in admitted patients . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03190759
Study type Observational
Source Assiut University
Contact . Moustafa El -Said, Professor
Phone 01110277000
Email moustafa13@yahoo.com
Status Not yet recruiting
Phase N/A
Start date November 11, 2017
Completion date October 20, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT02934945 - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Phase 4
Completed NCT02561351 - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation N/A
Recruiting NCT01759472 - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test N/A
Completed NCT01918293 - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult N/A
Completed NCT01203904 - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation N/A
Completed NCT01762917 - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing N/A
Completed NCT00536731 - Symbicort Rapihaler Therapeutic Equivalence Study Phase 3
Completed NCT00930826 - Childhood Asthma and Schooling: The Truth Unveiled N/A
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00327028 - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma Phase 4
Completed NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) Phase 3
Completed NCT00153283 - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma Phase 4
Completed NCT00950794 - Study of Salmeterol (SN408D) for Adult Asthma Phase 4
Completed NCT00142025 - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Phase 4
Completed NCT00153270 - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma Phase 4
Completed NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma Phase 2
Recruiting NCT05189613 - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis N/A
Recruiting NCT04128111 - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed NCT06326632 - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma N/A
Completed NCT05088512 - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population